What is Modulight Bio?
Modulight Bio is at the forefront of developing a precision neuromodulation platform that leverages optogenetics to address severe neurological disorders. The company's core mission is to deliver rapid and precise therapeutic relief for patients afflicted with conditions such as seizures, tremors, and neuropathic pain. Currently, Modulight Bio is focusing its clinical development efforts on trigeminal neuropathic pain as its initial indication. By harnessing the therapeutic potential of light, Modulight aims to revolutionize the treatment landscape for individuals managing debilitating neurological challenges.
How much funding has Modulight Bio raised?
Modulight Bio has raised a total of $12.2M across 1 funding round:
Seed
$12.2M
Seed (2025): $12.2M with participation from LocalGlobe, Jibe Ventures, Sara Capital, Secret Chord Ventures, and SilverArc Capital
Key Investors in Modulight Bio
LocalGlobe
LocalGlobe is an early-stage venture capital firm known for its investments in disruptive technologies and innovative startups. They typically support companies from their inception, providing crucial seed capital and strategic guidance to help founders scale their ventures.
Jibe Ventures
Jibe Ventures is an early-stage venture capital fund based in Israel, focusing on seed and pre-seed investments. The firm aims to foster genuine connections with founders, assisting them in various aspects such as team building, ideation, and go-to-market strategies.
Sara Capital
Sara Capital Group is a full-service provider of real estate solutions focused on multicultural markets in the Southeastern United States. The company offers a diverse range of services including acquisition and disposition, repositioning, property management, landlord and tenant representation, investment sales, and advisory services.
What's next for Modulight Bio?
With the recent major strategic investment, Modulight Bio is poised to accelerate the clinical validation of its optogenetics-based neuromodulation platform. This substantial backing, likely from investors with a keen interest in deep-tech healthcare solutions, signals a strong market belief in the company's innovative approach to treating neurological disorders. The company is expected to advance its trigeminal neuropathic pain program through clinical studies, with the ultimate goal of transforming patient care and establishing a new standard for precision neurological treatments. Future growth will likely involve expanding indications and potentially seeking further strategic partnerships to scale its technology.
See full Modulight Bio company page
